Загрузка...
The Clinical and Economic Burden of Hyperkalemia on Medicare and Commercial Payers
BACKGROUND: Hyperkalemia (serum potassium >5.0 mEq/L) may be caused by reduced kidney function and drugs affecting the renin-angiotensin-aldosterone system and is often present in patients with chronic kidney disease (CKD). OBJECTIVE: To quantify the burden of hyperkalemia in US Medicare fee-for-...
Сохранить в:
| Опубликовано в: : | Am Health Drug Benefits |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Engage Healthcare Communications, LLC
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5536196/ https://ncbi.nlm.nih.gov/pubmed/28794824 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|